Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Enveric Biosciences Inc. - news published 259 - readings 4.381

BACK

Enveric Biosciences Inc.

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Press Releases Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement By wpengine July 15, 2024 No Comments Aries to clinically develop and market Enveric's patented product for radiation dermatitis CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric"), a biotechnology company dedicated to the development of novel neuroplastog ...

15.07.2024

Enveric Biosciences Inc.

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement Form 8 K

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement Aries to clinically develop and market Enveric's patented product for radiation dermatitis CAMBRIDGE, Mass., July 15, 2024 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiat ...

15.07.2024

Enveric Biosciences Inc.

Enveric Biosciences Announces Patent Granted for Drug Candidate

Press Releases Enveric Biosciences Announces Patent Granted for Drug Candidate By wpengine July 10, 2024 No Comments US patent includes broad claims for treating brain neurological disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogens for th ...

10.07.2024

Enveric Biosciences Inc.

Registration Statement Specified Transactions Form S 3

As filed with the U.S. Securities and Exchange Commission on July 8, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4484725 (State or other jurisdiction of incorporation ...

08.07.2024

Enveric Biosciences Inc.

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Press Releases Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate By wpengine June 25, 2024 No Comments EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clin ...

25.06.2024

Enveric Biosciences Inc.

Initial Statement of Beneficial Ownership - Form 3

Ownership Submission FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per respo ...

03.06.2024

Enveric Biosciences Inc.

Enveric Biosciences to Participate in BIO International Convention 2024

Press Releases Enveric Biosciences to Participate in BIO International Convention 2024 By wpengine May 30, 2024 No Comments CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, an ...

30.05.2024

Enveric Biosciences Inc.

Submission of Matters to a Vote of Security Holders - Form 8-K

Item 5.07 Submission of Matters to a Vote of Security Holders. On May 28, 2024, Enveric Biosciences, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"). A total of 2,827,073 shares of the Company's common stock were present in person or represented by proxy at the 2024 Annual Meeting, which represented 38.75% of th ...

29.05.2024

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule - Form 8-K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 21, 2024, Enveric Biosciences, Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it regained compliance with the minimu ...

23.05.2024

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule - Form 8-K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 16, 2024, Enveric Biosciences, Inc. (the "Company") received a notification letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that, because the closing bid ...

17.05.2024

Enveric Biosciences Inc.

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results - Form 8-K

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results Revealed seven classes of promising novel drug candidates discovered using Enveric's Psybrary™ and PsyAI™ drug discovery and artificial intelligence (AI) platforms Launched business development campaign that resulted in the execution of seven non-binding term sheets with four strategic partners ...

15.05.2024

Enveric Biosciences Inc.

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

Press Releases Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders By wpengine May 14, 2024 No Comments MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic c ...

14.05.2024

Enveric Biosciences Inc.

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Press Releases Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids By wpengine May 8, 2024 No Comments Biotechnology licensee expected to progress methods targeting breast and other cancers using cannabinoids in combination with chemotherapeut ...

08.05.2024

Enveric Biosciences Inc.

Material Agreement - Form 8-K

Item 1.01 Entry Into a Material Definitive Agreement. On May 3, 2024, Enveric Biosciences, Inc., a Delaware corporation (the "Company") entered into a series of common stock purchase agreements (the "Purchase Agreements") for the issuance in a registered direct offering of an aggregate of 458,000 shares of the Company's common stock, par value $0.01 per sha ...

03.05.2024

Enveric Biosciences Inc.

Unlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology [Microdose]

Press Releases Unlocking New Horizons: Enveric Biosciences' Strategic Moves in Biotechnology [Microdose] By Enveric April 30, 2024 No Comments In a significant stride toward transforming the landscape of joint disease treatment, Enveric Biosciences has inked two non-binding term sheets with a yet undisclosed biotechnology company. This promising collaboration is poised to stee ...

30.04.2024

Enveric Biosciences Inc. - news published 259 - readings 4.381

Enveric Biosciences Inc.

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Enveric Biosciences Inc.

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement Form 8 K

Enveric Biosciences Inc.

Enveric Biosciences Announces Patent Granted for Drug Candidate

Enveric Biosciences Inc.

Registration Statement Specified Transactions Form S 3

Enveric Biosciences Inc.

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Enveric Biosciences Inc.

Initial Statement of Beneficial Ownership - Form 3

Enveric Biosciences Inc.

Enveric Biosciences to Participate in BIO International Convention 2024

Enveric Biosciences Inc.

Submission of Matters to a Vote of Security Holders - Form 8-K

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule - Form 8-K

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

Enveric Biosciences Inc.

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Enveric Biosciences Inc.

Material Agreement - Form 8-K

Enveric Biosciences Inc.

Unlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology [Microdose]

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member